Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer
Conditions
Keywords
EGF ointment, EGFR inhibitor, Skin side effect
Brief summary
The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC). Dermatological reactions can cause significant physical and psycho-social discomfort to patients. In the present study, the investigators evaluated the effect of epidermal growth factor (EGF) ointment on EGFR inhibitor-related skin side effects (ERSEs).
Detailed description
The current study includes patients diagnosed with advanced NSCLC or PC or CRC, with pathological confirmation. The inclusion criteria were NSCLC treated with erlotinib alone and PC treated with gemcitabine and erlotinib combination chemotherapy and CRC treated with cetuximab and5-Fluorouracil (5-FU)+Irinotecan+leucovorin(LV) (FOLFIRI), 5-FU+Oxaliplatin+LV (FOLFOX) and sufficient liver, kidney, and bone marrow function to undergo treatment. All the patients had Grade ≥2 ERSEs according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) v. 4.03. The patients will be randomized 3 groups; Placebo group, Arm 1, and Arm 2. Arm 1 will be treated with 1ppm concentration EGF ointment. Arm 2 will be treated with 20ppm concentration EGF ointment. And placebo group will be treated with 0ppm concentration EGF ointment.
Interventions
DRUGArm EGF ointment 1ppm
EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
DRUGArm EGF ointment 20 ppm
EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
DRUGArm Placebos
EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
Sponsors
Dong-A University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age: older than 20 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 3. Histologically confirmed lung cancer, pancreatic cancer, or colon cancer 4. Patients take EGFR inhibitor following the reason * EGFR mutation (+) NSCLC - adenocarcinoma for 1st line treatment * NSCLC - for ≥ 2nd line treatment * Pancreatic cancer - adenocarcinoma for 1st line treatment with Gemcitabine * Colon cancer - adenocarcinoma 1st line treatment with Irinotecan (FOLFIRI) 5. Patients who have EGFR inhibitor related skin side effects (ERSE) Gr≥2 (NCICTC V4.0) 6. A patient with the willingness to comply with the study protocol during the study period and capable of complying with it 7. A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages
Exclusion criteria
1. A patient with previous active or passive immunotherapy 2. A pregnant or lactating patient 3. A patient of childbearing potential without being tested for pregnancy at baseline for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.) 4. A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications 5. A patient with history of dermatologic care (except transient urticaria) within 4 weeks 6. A patient with clinically significant (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmias, etc) or myocardial infarction within past 12 months 7. A patient with interstitial pneumonia or diffused symptomatic fibrosis of the lungs. 8. Organ allogenic transplantation requiring immunosuppressive therapy. Any waiver of these inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To estimate the response rate of EGF ointment | 1 year | The effectiveness of the EGF ointment was defined as follows: 1. Grade 2, 3, or 4 ERSEs downgraded to ≤Grade 1 or 2. Grade 3 or 4 ERSEs downgraded to Grade 2 and persisting for at least two weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life | 1 year | To evaluate the patients' Quality of Life (QoL) by Skin evaluation method (SKINDEX-16) |
Countries
South Korea
Outcome results
None listed